09:06 AM EDT, 07/08/2024 (MT Newswires) -- Merus (MRUS) said Monday it has dosed first patient in its phase 2 trial of petosemtamab combined with standard chemotherapy to treat second-line metastatic colorectal cancer.

The open-label trial aims to evaluate the safety and preliminary antitumor activity of petosemtamab and chemotherapy in approximately 40 patients without prior EGFR inhibitor treatment.